Controls & Reference Materials

Seraseq® ctDNA EGFR G719S Mutation Mix AF01

Material Number 0710-0713
Size 1 x 20 uL
Inventory Status In Stock
Unit EA

Driver mutations in the EGFR, BRAF and KRAS genes represent a combined ~60% of all genomic variants driving oncogenesis of many solid tumor diseases, especially lung cancer. SeraCare is expanding its Seraseq liquid biopsy portfolio with the addition of low-plex (single-gene) reference materials for clinically-validated biomarkers as ground-truth standards for molecular testing of circulating tumor DNA patient samples by PCR or NGS technologies. These products are designed for validation and standardization of clinical biomarkers in CLIA/CAP-accredited laboratory developed tests (LDTs).

The Seraseq ctDNA EGFR G719S Mutation Mix product has an allele frequency of 0.1%.

  • Size distribution similar to native cfDNA
  • Offered as a purified DNA mixture for ease of use during processing
  • Mutation precisely quantitated with digital PCR
  • Single well-characterized GM24385 human genomic DNA as background wild-type material
  • Manufactured in GMP-compliant and ISO 13485-certified facilities

Seraseq ctDNA EGFR G719S Mutation Mix AF1% & AF0.1%

Doc type
Package Insert

Seraseq ctDNA EGFR G719S Mutation Mix AF0.1%

Doc type
Product Report
Lot #
Product Specifications
# of Variants 1
Allele Frequency 0.1%
Fragment Size ~170bp
Concentration 10 ng/µL
Fill Size 20 µL
Total DNA 200 ng
Buffer Tris/EDTA (TE)